MX346090B - Derivados de pirrolidina usados como inhibidores de catepsina. - Google Patents

Derivados de pirrolidina usados como inhibidores de catepsina.

Info

Publication number
MX346090B
MX346090B MX2013004667A MX2013004667A MX346090B MX 346090 B MX346090 B MX 346090B MX 2013004667 A MX2013004667 A MX 2013004667A MX 2013004667 A MX2013004667 A MX 2013004667A MX 346090 B MX346090 B MX 346090B
Authority
MX
Mexico
Prior art keywords
derivatives used
pyrrolidine derivatives
cathepsin inhibitors
cathepsin
inhibitors
Prior art date
Application number
MX2013004667A
Other languages
English (en)
Other versions
MX2013004667A (es
Inventor
Banner David
Haap Wolfgang
Kuehne Holger
Plancher Jean-Marc
Grether Uwe
Mauser Harald
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013004667A publication Critical patent/MX2013004667A/es
Publication of MX346090B publication Critical patent/MX346090B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I) (Ver Formula) en la que de A1 a A4 y de R1 a R6 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
MX2013004667A 2010-11-05 2011-11-02 Derivados de pirrolidina usados como inhibidores de catepsina. MX346090B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190239 2010-11-05
PCT/EP2011/069219 WO2012059507A1 (en) 2010-11-05 2011-11-02 Pyrrolidine derivatives used as cathepsin inhibitors

Publications (2)

Publication Number Publication Date
MX2013004667A MX2013004667A (es) 2013-06-28
MX346090B true MX346090B (es) 2017-03-07

Family

ID=43645895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004667A MX346090B (es) 2010-11-05 2011-11-02 Derivados de pirrolidina usados como inhibidores de catepsina.

Country Status (12)

Country Link
US (1) US8524710B2 (es)
EP (1) EP2635562B1 (es)
JP (1) JP5670580B2 (es)
KR (1) KR101522119B1 (es)
CN (1) CN103201274B (es)
AR (1) AR083700A1 (es)
BR (1) BR112013010699A2 (es)
CA (1) CA2815611C (es)
ES (1) ES2512445T3 (es)
MX (1) MX346090B (es)
RU (1) RU2548684C2 (es)
WO (1) WO2012059507A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120921A1 (en) 2012-02-17 2013-08-22 F. Hoffmann-La Roche Ag Novel pyrrolidine derivatives
EP2840083B1 (en) * 2012-04-17 2017-09-13 Astellas Pharma Inc. Nitrogenated bicyclic aromatic heterocyclic compound
EP3055314B1 (en) * 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
AU2018211735B2 (en) 2017-01-24 2021-08-12 Astellas Pharma Inc. Phenyldifluoromethyl-substituted prolinamide compound
EP4617267A4 (en) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Thioether compound having mild medicinal properties and its use, pharmaceutical composition and associated uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02006163A (es) 1999-12-24 2002-12-05 Hoffmann La Roche Derivados de nitrilo como inhibidores de la catepsina k.
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
CL2007003100A1 (es) * 2006-10-30 2008-04-18 Glaxo Group Ltd Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
ES2436550T3 (es) 2009-04-20 2014-01-02 F. Hoffmann-La Roche Ag Nuevos derivados de prolina como inhibidores de catepsina

Also Published As

Publication number Publication date
JP2013541574A (ja) 2013-11-14
US20120115843A1 (en) 2012-05-10
RU2548684C2 (ru) 2015-04-20
US8524710B2 (en) 2013-09-03
KR101522119B1 (ko) 2015-05-20
CN103201274B (zh) 2014-08-20
JP5670580B2 (ja) 2015-02-18
BR112013010699A2 (pt) 2016-08-09
ES2512445T3 (es) 2014-10-24
WO2012059507A1 (en) 2012-05-10
EP2635562B1 (en) 2014-09-03
CN103201274A (zh) 2013-07-10
MX2013004667A (es) 2013-06-28
AR083700A1 (es) 2013-03-13
CA2815611A1 (en) 2012-05-10
RU2013124993A (ru) 2014-12-10
EP2635562A1 (en) 2013-09-11
KR20130089265A (ko) 2013-08-09
CA2815611C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
MY153880A (en) Proline derivatives as cathepsin inhibitors
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MX338327B (es) Inhibidores de cdk.
PH12015501083A1 (en) Novel pyridine derivatives
NZ597517A (en) 5-fluoropyrimidinone derivatives
UA118666C2 (uk) Похідні піразолу
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MY182328A (en) Pyridine-2-amides useful as cb2 agonists
PH12013500942A1 (en) Triazolopyridine compounds
MX349373B (es) Nuevos derivados de pirazina.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
NZ595705A (en) Protease inhibitors
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
IN2012DN00765A (es)
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.
MX2014008141A (es) Amidas macrociclicas como inhibidores de proteasas.
GEP20156244B (en) New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof
MX2014008918A (es) Nuevos derivados de pirrolidina.
IN2014DN10669A (es)
MX2013003498A (es) Derivados de cromeno.
MX363458B (es) Nuevos derivados de tetrazolona.
PH12015500262A1 (en) Novel pyridine derivatives
MX2011007641A (es) Nuevos compuestos heterociclicos como inhibidores de metap-2.

Legal Events

Date Code Title Description
FG Grant or registration